Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective
Marked differences in costs between subcutaneous and intravenous therapies were observed. Among the three groups of patients defined by TNF inhibitor treatment, costs for the infliximab group were highest during the year after the index event. </AbstractSection> Copyright Zeidler et al.; licensee Springer. 2012
Year of publication: |
2012
|
---|---|
Authors: | Zeidler, Jan ; Mittendorf, Thomas ; Müller, Rüdiger ; Kempis, Johannes von |
Published in: |
Health Economics Review. - Springer. - Vol. 2.2012, 1, p. 1-8
|
Publisher: |
Springer |
Subject: | Inflammatory rheumatic diseases | Claims data | Cost analysis | Dosing patterns | Switzerland | Tumor necrosis factor inhibitor |
Saved in:
Online Resource